The role of UPR‐related long noncoding RNAs in development of endocrine resistance in breast cancer

Breast cancer patients who express estrogen receptor α (ER) typically receive endocrine therapy as a first‐line treatment. Most ER‐positive breast cancer patients initially respond to endocrine therapy, but up to 40% of patients develop resistance over time, and the main mechanism is aberrant activa...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer Vol. 157; no. 12; pp. 2434 - 2446
Main Authors: Liu, Wen, Gupta, Sahil, Gupta, Sanjeev
Format: Journal Article
Language:English
Published: Hoboken, USA John Wiley & Sons, Inc 15.12.2025
Wiley Subscription Services, Inc
Subjects:
Animals
Antineoplastic Agents, Hormonal - pharmacology
Antineoplastic Agents, Hormonal - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cell fate
Drug Resistance, Neoplasm - genetics
endocrine resistance
Endocrine therapy
Endoplasmic reticulum
Endoplasmic Reticulum Stress - genetics
Estrogen receptors
Female
Gene Expression Regulation, Neoplastic
Humans
long noncoding RNA
Microenvironments
Non-coding RNA
Patients
Protein folding
RNA, Long Noncoding - genetics
Signal Transduction
unfolded protein response
Unfolded Protein Response - genetics
long noncoding RNA
unfolded protein response
breast cancer
endocrine resistance
ISSN:0020-7136, 1097-0215, 1097-0215
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer patients who express estrogen receptor α (ER) typically receive endocrine therapy as a first‐line treatment. Most ER‐positive breast cancer patients initially respond to endocrine therapy, but up to 40% of patients develop resistance over time, and the main mechanism is aberrant activation of ER signaling pathways. Recent research has shown that cancer's uncontrolled proliferative capacity and a hostile microenvironment can induce endoplasmic reticulum (EnR) stress and trigger unfolded protein response (UPR), which plays a crucial role in determining cell fate. Furthermore, increasing evidence suggests that noncoding ribonucleic acids (RNAs), which are involved during the crosstalk between the UPR and ER signaling pathways, play an essential role in endocrine resistance. In this review, we provide an overview of long noncoding RNA (lncRNA) that is involved both in endocrine resistance and UPR. We provide new insights into potential treatment strategies to overcome endocrine resistance in ER‐positive breast cancer patients by targeting the lncRNA that plays key roles in endocrine resistance and UPR signaling. Finally, we discuss the current state and future directions for targeting lncRNAs to improve clinical outcomes in endocrine‐resistant breast cancer patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0020-7136
1097-0215
1097-0215
DOI:10.1002/ijc.70067